XML 22 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Balance Sheet Details
6 Months Ended
Jun. 30, 2023
Balance Sheet Related Disclosures [Abstract]  
Balance Sheet Details

2. Balance Sheet Details

Property, Plant and Equipment, net

Property, plant and equipment, net, consist of the following (in thousands):

 

 

June 30,

 

 

December 31,

 

 

 

2023

 

 

2022

 

Computer equipment and software

 

$

1,090

 

 

$

1,078

 

Furniture and fixtures

 

 

1,089

 

 

 

1,086

 

Leasehold improvements

 

 

115

 

 

 

115

 

Construction in process

 

 

604

 

 

 

399

 

Total property, plant and equipment, gross

 

 

2,898

 

 

 

2,678

 

Less: accumulated depreciation

 

 

(1,740

)

 

 

(1,471

)

Total property, plant and equipment, net

 

$

1,158

 

 

$

1,207

 

 

Depreciation expense for each of the three months ended June 30, 2023 and 2022 was approximately $0.1 million. Depreciation expense for each of the six months ended June 30, 2023 and 2022 was approximately $0.3 million. No property, plant or equipment was disposed of during the six months ended June 30, 2023 or the year ended December 31, 2022.

Accrued Expenses

Accrued expenses consist of the following (in thousands):

 

 

June 30,

 

 

December 31,

 

 

 

2023

 

 

2022

 

Accrued research and development expenses

 

$

6,716

 

 

$

3,080

 

Accrued compensation expenses

 

 

6,531

 

 

 

8,447

 

Accrued professional & consulting expenses

 

 

2,183

 

 

 

3,000

 

Accrued other

 

 

21

 

 

 

151

 

Total accrued expenses

 

$

15,451

 

 

$

14,678

 

 

Inventory

Inventory consist of the following (in thousands):

 

 

June 30,

 

 

December 31,

 

 

 

2023

 

 

2022

 

Raw materials

 

$

111

 

 

$

 

Total inventory, current

 

$

111

 

 

$

 

Raw materials, noncurrent

 

 

3,450

 

 

 

 

Total inventory

 

$

3,561

 

 

$

 

Raw materials consist of materials, including active pharmaceutical ingredients, to be consumed in the production of inventory related to the FDA approved products. $3.5 million of raw materials are included within other long-term assets as of June 30, 2023.